Mon, May 9, 2016
Fri, May 6, 2016
Thu, May 5, 2016
Wed, May 4, 2016
Tue, May 3, 2016
Mon, May 2, 2016
Sun, May 1, 2016
Fri, April 29, 2016
Thu, April 28, 2016

Paul Matteis Maintained (ALNY) at Buy with Decreased Target to $107 on, May 3rd, 2016

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. ith-decreased-target-to-107-on-may-3rd-2016.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $120 to $107 on, May 3rd, 2016.

Paul has made no other calls on ALNY in the last 4 months.



There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Paul


  • Keay Nakae of "Chardan Capital" Initiated at Strong Buy and Held Target at $93 on, Monday, April 4th, 2016
  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Decreased Target to $81 on, Friday, March 11th, 2016
  • Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $154 on, Wednesday, January 20th, 2016